Drugs / ALFQ
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT06205056 Background | Jan 2024 → Dec 2025 overdue | HIV infectious disease | U.S. Army Medical Research and Development Command | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALFQ | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06205056 ↗ |
| Route | Intramuscular | “All products will be administered by intramuscular (IM) injection into the same quadriceps muscle at each product administration visit.” NCT06205056 ↗ |